Analyst Price Targets — ZNTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 22, 2026 10:56 am | Andrew Fein | H.C. Wainwright | $10.00 | $4.14 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL) |
| April 10, 2026 10:56 am | — | Guggenheim | $10.00 | $6.14 | TheFly | Zentalis price target raised to $10 from $6 at Guggenheim |
| November 11, 2025 9:50 am | Andrew Berens | Leerink Partners | $2.00 | $1.32 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2 at Leerink Partners |
| June 18, 2024 2:17 pm | Akash Tewari | Jefferies | $6.00 | $4.31 | TheFly | Zentalis downgraded to Hold from Buy at Jefferies |
| June 18, 2024 1:32 pm | Matthew Harrison | Morgan Stanley | $8.00 | $4.14 | StreetInsider | Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight |
| June 18, 2024 11:46 am | Bradley Canino | Stifel Nicolaus | $10.00 | $5.39 | TheFly | Zentalis price target lowered to $10 from $32 at Stifel |
| June 18, 2024 10:45 am | Robert Driscoll | Wedbush | $4.00 | $5.70 | TheFly | Wedbush downgrades Zentalis to Underperform on unclear azeno path forward |
| May 7, 2024 4:31 pm | Bradley Canino | Stifel Nicolaus | $32.00 | $12.43 | StreetInsider | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $32 at Stifel |
| November 14, 2022 9:32 am | — | Wedbush | $32.00 | $22.56 | Benzinga | Wedbush Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $32 |
| November 11, 2022 9:12 am | — | Morgan Stanley | $55.00 | $20.90 | Benzinga | Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Lowers Price Target to $55 |
Latest News for ZNTL
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at…
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to…
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced the appointments of Shannon Campbell to its Board of Directors and Sarah Kelly as the Company's Senior Vice President of…
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7. 3-month median PFS In the 250 mg QD 5:2 intermittent dose cohort, 50% ORR, 9.
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZNTL.
U.S. House Trading
No House trades found for ZNTL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.